Substitution of a hydrogen atom with its heavy isotope deuterium entails the addition of one
neutron to a molecule. Despite being a subtle change, this structural modification, known as …

Our incomplete understanding of the causes and pathways involved in the onset and
progression of multiple sclerosis (MS) limits our ability to effectively treat this complex …

The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …

Background Effective, well-tolerated oral psoriasis treatments are needed. Objective To
compare the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine …

Background Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, inhibits
cytokine signaling in psoriasis pathogenesis. Objective The objective of this study was to …

Psoriasis is a chronic inflammatory disease characterised by sharply demarcated
erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by …

An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer
and activator of transcription (STAT) signalling in multiple disease states has led to an …

Objective To assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric
inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus …

Despite recent advances in the treatment of autoimmune and inflammatory diseases, unmet
medical needs in some areas still exist. One of the main therapeutic approaches to alleviate …

Deucravacitinib (SOTYKTU™) is a first-in-class, highly selective, oral tyrosine kinase 2
(TYK2) inhibitor. It acts via an allosteric mechanism, binding to the catalytically inactive …